A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

Pfizer gains attention with strong performance, reinforcing its role in the Russell 1000 Index and strengthening its position ...

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

An advantage of antibody-drug conjugates (ADCs) is that they allow targeted delivery of cytotoxic agents into tumors, thus improving the therapeutic index. Pfizer Inc. has developed a new ADC, ...